Low-dose cytosine arabinoside as remission induction therapy in refractory adult acute lymphocytic leukemia

Páll T. Önundarson; Jacob M. Rowe

doi:10.1016/0002-9343(89)90357-4

ScienceGate Book Chapters

JOURNAL ARTICLE

Low-dose cytosine arabinoside as remission induction therapy in refractory adult acute lymphocytic leukemia

Páll T. Önundarson Jacob M. Rowe

Year: 1989 Journal: The American Journal of Medicine Vol: 86 (4)Pages: 493-494 Publisher: Elsevier BV

DOI: 10.1016/0002-9343(89)90357-4

Get Full-Text PDF Get Analytical Report

Keywords:

Medicine Refractory (planetary science) Cytosine Induction therapy Cytarabine Leukemia Internal medicine Acute lymphocytic leukemia Oncology Chemotherapy Lymphoblastic Leukemia

Metrics

Cited By

1.64

FWCI (Field Weighted Citation Impact)

Refs

0.83

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Acute Lymphoblastic Leukemia research

Health Sciences → Medicine → Public Health, Environmental and Occupational Health

Chronic Lymphocytic Leukemia Research

Health Sciences → Medicine → Genetics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Low-dose cytosine arabinoside as remission induction therapy in refractory adult acute lymphocytic leukemia

Metrics

Topics

Related Documents

Low-dose cytosine arabinoside in relapsed acute lymphocytic leukemia

High-dose cytosine arabinoside therapy in acute non-lymphocytic leukemia

High-dose cytosine arabinoside therapy for refractory leukemia

Intermediate-Dose Cytosine Arabinoside and Amsacrine for Remission Induction and High-Dose Cytosine Arabinoside and Amsacrine for Intensive Consolidation in Relapsed and Refractory Adult Acute Myelogenous Leukemia

High-dose cytosine arabinoside therapy for refractory leukemia